Literature DB >> 10948119

Genetic polymorphisms of group B streptococcus scpB alter functional activity of a cell-associated peptidase that inactivates C5a.

J F Bohnsack1, S Takahashi, L Hammitt, D V Miller, A A Aly, E E Adderson.   

Abstract

Many group B Streptococcus agalactiae strains and other pathogenic streptococci express a cell-associated peptidase that inactivates C5a (C5a-ase), the major neutrophil chemoattractant produced by activation of the complement cascade. Type III group B streptococci (GBS) can be classified genotypically into three restriction digest pattern types. Functional C5a-ase activity of GBS correlates with this genetic typing; therefore, we sought to identify a genetic basis for this phenomenon. Southern hybridization confirms that all type III GBS contain scpB, the gene encoding GBS C5a-ase. GBS strains with high C5a-ase functional activity and those with no or very low activity both express immunoreactive C5a-ase. The scpB sequence of strain I30, which has high C5a-ase activity, is 98.2% homologous to the previously reported serotype II GBS scpB sequence. The scpB sequences of strains I25 and GW, which have low or no C5a-ase activity, are identical. The predicted I25 and GW C5a-ase proteins share a four-amino-acid deletion affecting the protease histidine active-site consensus motif. Recombinant I30 C5a-ase has good functional activity, whereas recombinant I25 C5a-ase has low activity. These data demonstrate that functional C5a-ase differences between type III GBS strains are attributable to a genetic polymorphism of scpB. The ubiquitous expression of C5a-ase, irrespective of functional activity, suggests that C5a-ase may have a second, as yet unidentified, function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948119      PMCID: PMC101725          DOI: 10.1128/IAI.68.9.5018-5025.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Virulent human strains of group G streptococci express a C5a peptidase enzyme similar to that produced by group A streptococci.

Authors:  P P Cleary; J Peterson; C Chen; C Nelson
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

2.  Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus.

Authors:  J F Bohnsack; K W Mollison; A M Buko; J C Ashworth; H R Hill
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

3.  Identification of a highly encapsulated, genetically related group of invasive type III group B streptococci.

Authors:  S Takahashi; E E Adderson; Y Nagano; N Nagano; M R Briesacher; J F Bohnsack
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

4.  Group B streptococci inhibit the chemotactic activity of the fifth component of complement.

Authors:  H R Hill; J F Bohnsack; E Z Morris; N H Augustine; C J Parker; P P Cleary; J T Wu
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

5.  Complete nucleotide sequence of the streptococcal C5a peptidase gene of Streptococcus pyogenes.

Authors:  C C Chen; P P Cleary
Journal:  J Biol Chem       Date:  1990-02-25       Impact factor: 5.157

Review 6.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

7.  Molecular studies of Ssa1, a serotype-specific antigen of Pasteurella haemolytica A1.

Authors:  R Y Lo; C A Strathdee; P E Shewen; B J Cooney
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

8.  Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide.

Authors:  E E Adderson; P G Shackelford; A Quinn; W L Carroll
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

9.  Human neutrophil chemotactic response to group A streptococci: bacteria-mediated interference with complement-derived chemotactic factors.

Authors:  D E Wexler; R D Nelson; P P Cleary
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

10.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

View more
  15 in total

1.  Identification of novel adhesins from Group B streptococci by use of phage display reveals that C5a peptidase mediates fibronectin binding.

Authors:  Christiane Beckmann; Joshua D Waggoner; Theresa O Harris; Glen S Tamura; Craig E Rubens
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 2.  Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.

Authors:  Gunnar Lindahl; Margaretha Stålhammar-Carlemalm; Thomas Areschoug
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.

Authors:  Qi Cheng; Steven Debol; Hong Lam; Ron Eby; Lorri Edwards; Yury Matsuka; Stephen B Olmsted; P Patrick Cleary
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

4.  Evaluation of the ability of Streptococcus agalactiae strains isolated from genital and neonatal specimens to bind to human fibrinogen and correlation with characteristics of the fbsA and fbsB genes.

Authors:  Agnès Rosenau; Karine Martins; Souheila Amor; François Gannier; Philippe Lanotte; Nathalie van der Mee-Marquet; Laurent Mereghetti; Roland Quentin
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

5.  A novel streptococcal surface protease promotes virulence, resistance to opsonophagocytosis, and cleavage of human fibrinogen.

Authors:  Theresa O Harris; Daniel W Shelver; John F Bohnsack; Craig E Rubens
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

6.  Human serum induces streptococcal c5a peptidase expression.

Authors:  Ute Gleich-Theurer; Simone Aymanns; Gregor Haas; Stefanie Mauerer; Julia Vogt; Barbara Spellerberg
Journal:  Infect Immun       Date:  2009-06-08       Impact factor: 3.441

7.  Selection, recombination, and virulence gene diversity among group B streptococcal genotypes.

Authors:  A Cody Springman; David W Lacher; Guangxi Wu; Nicole Milton; Thomas S Whittam; H Dele Davies; Shannon D Manning
Journal:  J Bacteriol       Date:  2009-07-06       Impact factor: 3.490

8.  Multilocus sequence typing system for group B streptococcus.

Authors:  Nicola Jones; John F Bohnsack; Shinji Takahashi; Karen A Oliver; Man-Suen Chan; Frank Kunst; Philippe Glaser; Christophe Rusniok; Derrick W M Crook; Rosalind M Harding; Naiel Bisharat; Brian G Spratt
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

9.  High-affinity interaction between fibronectin and the group B streptococcal C5a peptidase is unaffected by a naturally occurring four-amino-acid deletion that eliminates peptidase activity.

Authors:  Glen S Tamura; James R Hull; Michael D Oberg; David G Castner
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

10.  Epidemiology of and prenatal molecular distinction between invasive and colonizing group B streptococci in The Netherlands and Taiwan.

Authors:  E van Elzakker; R Yahiaoui; C Visser; P Oostvogel; A Muller; Y-R Ho; J-J Wu; A van Belkum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-03-31       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.